title: Bullish sentiment stays (mostly) high for investments in cancer drugs and biotechnology.
authors: J
authors: J
authors: Roemer
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000191:economics; D001709:Biotechnology / Q000191:economics; D004345:Drug Industry / Q000191:economics; D015507:Drugs, Investigational / Q000191:economics; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D000069283:Rituximab; D014481:United States
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D015507:Drugs, Investigational; D000069283:Rituximab